Exchange Traded Concepts, LLC Eagle Pharmaceuticals, Inc. Transaction History

Exchange Traded Concepts, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 18, 2023	BUY	$15.21 - $22.88 $353,008 - $531,021	23,209 New	23,209 $366,000
Q4 2022 Jan 17, 2023	BUY	$24.98 - $39.77 $25,279 - $40,247	1,012 Added 3.14%	33,257 $972,000
Q3 2022 Oct 07, 2022	BUY	$26.42 - $47.12 $39,603 - $70,632	1,499 Added 4.88%	32,245 $852,000
Q2 2022 Jul 20, 2022	BUY	$41.26 - $51.35 $37,629 - $46,831	912 Added 3.06%	30,746 $1.37 Million
Q1 2022 Apr 26, 2022	BUY	$44.58 - $52.6 $1.33 Million - $1.57 Million	29,834 New	29,834 $1.48 Million
Q3 2021 Oct 18, 2021	SELL	$43.79 - $55.78 $1 Million - $1.28 Million	-22,897 Closed	0 $0
Q2 2021 Jul 30, 2021	BUY	$36.86 - $44.5 $79,986 - $96,565	2,170 Added 10.47%	22,897 $980,000
Q1 2021 Apr 20, 2021	BUY	$40.32 - $50.97 $265,023 - $335,025	6,573 Added 46.44%	20,727 $865,000
Q4 2020 Jan 19, 2021	BUY	$41.72 - $51.34 $57,072 - $70,233	1,368 Added 10.7%	14,154 $659,000
Q3 2020 Oct 30, 2020	BUY	$37.02 - $51.28 $263,323 - $364,754	7,113 Added 125.38%	12,786 $543,000
Q2 2020 Jul 15, 2020	BUY	$43.24 - $55.02 $245,300 - $312,128	5,673 New	5,673 $272,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Exchange Traded Concepts, LLC, based on Form 13F filings with the SEC.

Stay updated on Exchange Traded Concepts, LLC with notifications on news.